Evidence map›Paper›PMID 35997778›Full record

ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2022

[Human Biomonitoring for Europe (HBM4EU)-first insights into the results of the initiative].

Philipp Weise, Petra Apel, Marike Kolossa-Gehring

Abstract readReview
In one paragraph

Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Philipp WeiseFG II 1.2 Toxikologie, gesundheitsbezogene Umweltbeobachtung, Umweltbundesamt, Corrensplatz 1, 14195, Berlin, Deutschland. philipp.weise@uba.de.
Petra ApelFG II 1.2 Toxikologie, gesundheitsbezogene Umweltbeobachtung, Umweltbundesamt, Corrensplatz 1, 14195, Berlin, Deutschland.
Marike Kolossa-GehringFG II 1.2 Toxikologie, gesundheitsbezogene Umweltbeobachtung, Umweltbundesamt, Corrensplatz 1, 14195, Berlin, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human biomonitoring measures the internal exposure of humans to chemicals from various sources, such as food, everyday objects, or the air we breathe, by analyzing blood and urine, for example. To promote and coordinate human biomonitoring in Europe, the European Human Biomonitoring Initiative (HBM4EU) was launched in 2017 and involves 30 countries, the European Environment Agency, and the European Commission. The project was completed in June 2022.Comparable and reliable exposure data were collected and consistently assessed for a wide range of environmental chemicals. Other important achievements of the initiative were the establishment of a quality assurance program, a concept for standardizing future HBM studies, a common strategy for deriving health-based guidance values (HBM-GVs), and the establishment of national committees in the partner countries. The exposure data generated are accessible via the Information Platform for Chemical Monitoring (IPCHEM) and the EU HBM Dashboard. Publications are freely available through the HBM4EU online library.Overall, the results show that exposures of the EU population to many chemicals are too high, such as phthalates and perfluorinated alkyl substances (PFAS), and that policy action is still needed. The knowledge generated in the HBM4EU project can support policymakers in improving chemical, environment, and health policies.

Indexed as

Biological MonitoringEnvironmental MonitoringEuropeGermanyHealth PolicyHumansChemical policyExposureHBMInternal pollutionRisk assessment

Identifiers

PMID35997778
PMCPMC9436871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.